Technical Data
Bromodeoxyuridine (BrdU)
Bromodeoxyuridine (BrdU) is a thymidine analog and is specifically incorporated into DNA during DNA synthesis. Anti-bromodeoxyuridine monoclonal antibody is used to identify cells that have incorporated BrdU. This immunological detection scheme has several advantages over the use of radioactive thymidine incorporation for identifying cells under-going replication. Labeling and detection can be performed the same day instead of waiting several days, as required for autoradiography of tritium-labeled cells, and the necessity of using multiple specimens for obtaining the optimal exposure time is eliminated. In addition, anti-bromodeoxyuridine staining with flow cytometric analysis allows multiple parameters to be evaluated simultaneously.

Applications: Immunocytochemistry Flow Cytometry
100ul-20CBlue IceMouse
Not determined
Culture supernatant.
Liquid. Contains no preservative.
Binds to bromodeoxyuridine and crossreacts with iodouridine (10%). Does not crossreact with fluorodeoxyuridine, nor with any endogenous cellular components such as thymidine or uridine.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Gonchoroff, NJ et al. A monoclonal antibody reactive with 5-Bromo-2- deoxyuridine that does not require DNA denaturation. Cytometry. 6:506512, 1985. Greipp, PR et al. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol. 20:289292, 1985. Gonchoroff, NJ et al. S-phase detection with an antibody to bromodeoxyuridine. Role of Dnase pretreatment. J. Immunol. Methods. 97:97- 101, 1986. Greipp, PR et al. Immunofluorescent labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 62:969977, 1987.